Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 10:32 AM
Ignite Modification Date: 2025-12-26 @ 10:32 AM
NCT ID: NCT02295228
Eligibility Criteria: Inclusion Criteria: * Elective total hip arthroplasty for osteoarthritis * Age 50+ * Able and willing to sign informed consent * English speaking * Willing to not alter vitamin D supplementation use for the duration of this study * Willing to utilize sunscreen of SPF-15 or higher when sun exposure for more than 15 minutes is expected Exclusion Criteria: * Illnesses known to affect inflammatory marker status including, but not limited to, rheumatoid arthritis, systemic lupus erythematosis and mixed connective tissue disease * Chronic diseases that could potentially affect DBP status, e.g., chronic kidney disease stage requiring dialysis, nephrotic syndrome and chronic hepatitis, * Hip arthritis from causes other than osteoarthritis * Treatment with medications with potential to affect vitamin D metabolism, (e.g., phenytoin, phenobarbital, teriparatide or active vitamin D analogues) or to potentially interfere with 25(OH)D measurement by HPLC (atavaquone) within the preceding three months. * Treatment with high dose vitamin D supplementation (50,000 IU weekly or more frequently) within the preceding three months. Note; subjects on a stable daily vitamin D dose will be allowed to participate * Surgical procedure within the preceding six months * Use of tanning beds or salons or unwillingness to utilize sunscreen during periods of sun exposure of 15 minutes or longer
Healthy Volunteers: True
Sex: ALL
Minimum Age: 50 Years
Study: NCT02295228
Study Brief:
Protocol Section: NCT02295228